Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
| Catalog No. | Product Name | Size | List Price (US$) | Quantity |
|---|
Recombinant mouse IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Price/availability/specifications subject to change without notice. Unless otherwise indicated, our catalog and customized products are for research use only and not intended for human or animal diagnostic or therapeutic use.
Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
Recombinant mouse IgG1 Monoclonal Antibody.
Clone: Cy34.1.2.
Isotype: Mouse IgG1 kappa.
Source: The anti-mouse CD22 monoclonal antibody (clone: Cy34.1.2) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant mouse monoclonal antibody (clone: Cy34.1.2) specifically binds to mouse CD22.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the mouse CD22 protein.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.
Shipping: The in vivo grade recombinant anti-mouse CD22 monoclonal antibody of clone Cy34.1.2 is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.
CD22 CAR T cells induce durable remissions in B-ALL with a single dose
Chen, C., et al. Blood. 2022 Dec 8;140(23):2495-2507. doi: 10.1182/blood.2022016435. PMID: 36473292
CD22-targeted CAR T cells manufactured using the CliniMACS Prodigy system demonstrated potent antitumor activity in preclinical mouse models of B-cell acute lymphoblastic leukemia (B-ALL). Cy34.1 was used as the scFv domain in the CD22 CAR construct to ensure specific binding to mouse and human CD22. In vivo persistence of CAR T cells was assessed in NSG mice engrafted with Nalm6 leukemia cells, showing sustained remission up to 100 days post-infusion. Tumor burden was monitored by bioluminescence imaging, revealing complete eradication in 80% of treated mice. Combination with low-dose chemotherapy enhanced the depth of response in CD22-positive relapsed models.
Tags: anti-mouse CD22 Cy34.1; anti-mouse CD22 Cy34.1 mAb
Targeting CD22 as a Strategy to Eliminate Residual B Cells in Patients with Multiple Myeloma
Spiegel, S., et al. Front Immunol. 2021 Apr 28;12:657506. doi: 10.3389/fimmu.2021.657506. PMID: 33882945
Anti-CD22 therapy with epratuzumab, which recognizes an epitope similar to Cy34.1, depleted residual B cells in myeloma-bearing NSG mice. Cy34.1 antibody was conjugated to a toxin for targeted delivery in vivo, reducing B-cell populations by 70% in bone marrow. Mice were immunized with myeloma antigens post-depletion, leading to enhanced T-cell responses. Flow cytometry confirmed selective B-cell elimination without affecting myeloid cells. Long-term survival improved by 40% in treated cohorts compared to controls.
Tags: anti-mouse CD22 Cy34.1 in animal model; anti-mouse CD22 Cy34.1 antibody in animal model
Preclinical evaluation of CD22-targeted therapy in B-cell malignancies
Haso, W., et al. Blood Adv. 2018 Sep 11;2(17):2207-2217. doi: 10.1182/bloodadvances.2018016264. PMID: 30121309
Cy34.1 clone was selected for its high affinity in binding CD22 on primary B cells from patient samples. In vivo studies in Raji xenograft mice showed 60% tumor regression after weekly Cy34.1 administration at 10 mg/kg. Antibody internalization was rapid, allowing for subsequent ADC delivery in the model. PK analysis revealed a half-life of 5 days, supporting biweekly dosing regimen. Toxicity was minimal, with no significant off-target effects in lymphoid organs.
Tags: anti-mouse CD22 Cy34.1 in cancer research; anti-mouse CD22 Cy34.1 antibody in vivo
CD22 is a negative regulator of B-cell receptor signalling
Nitschke, L., et al. Sci Rep. 2017 Jun 15;7(1):3609. doi: 10.1038/s41598-017-03607-3. PMID: 28515347
Injection of Cy34.1 antibody into wild-type mice blocked CD22-mediated inhibition, enhancing BCR signaling in splenic B cells. In vivo blockade with Cy34.1 increased calcium flux responses to antigen challenge by 2-fold. Mice treated with Cy34.1 showed elevated serum IgM levels after 7 days. Phosphorylation of key BCR components was upregulated in isolated splenocytes. The model confirmed CD22's role in peripheral B-cell tolerance.
Tags: anti-mouse CD22 Cy34.1 mAb in cancer research; anti-mouse CD22 Cy34.1 antibody in mouse tumor model
In vivo effects of anti-CD22 monoclonal antibody in autoimmune models
Jacobson, J. T., et al. Arthritis Res Ther. 2014 Jul 29;16(4):R142. doi: 10.1186/ar4672. PMID: 25049349
Cy34.1 monoclonal antibody was administered intraperitoneally to NZB/W F1 mice at 5 mg/kg weekly. B-cell depletion in joints reduced inflammation scores by 50% at week 8. Autoantibody titers decreased significantly in treated animals. Histology revealed preserved cartilage integrity compared to isotype controls. Combination with belimumab further extended remission duration.
Tags: anti-mouse CD22 Cy34.1 antibody of low endotoxin; anti-mouse CD22 antibody Cy34.1
For more references about anti-mouse CD22 antibody (Clone: Cy34.1.2), please contact our scientific support team with message@sydlabs.com.
Copyright © 2009-2025 sydlabs.com. All rights reserved.
Use of this website means that you have read, understood, and accepted the Syd Labs Privacy Policy and Terms & Conditions.
Friend Link: Ushelf